Trials in pregnant women in Kenya show that combining the standard malaria drug for pregnant women with high doses of folic acid make the malaria treatment twice as likely to fail. The findings, published in PLoS Clinical Trials yesterday (19 October), could mean that countries using Sulfadoxine pyrimethamine (SP) to treat malaria in pregnancy may need to reconsider their national guidelines for folic acid supplementation.